Nvidia’s Bold Move: Tackling Tech’s $1 Trillion Crisis

Taiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as 4,744%. Now, if you’re like everybody else, you want to know what Nvidia’s doing next … and who they’re going to partner with …

Find out details on these three critical Nvidia partners immediately.

Daniel R. Chevallard net worth and biography

Daniel Chevallard Biography and Net Worth

CFO of Viracta Therapeutics

Mr. Chevallard has served as Chief Financial Officer of Viracta since July 2019 and Chief Operating Officer since March 2021. Previously, Mr. Chevallard served as the Chief Financial Officer and principal financial officer at Regulus Therapeutics from May 2017 to July 2019. Mr. Chevallard joined Regulus Therapeutics in December 2012 as Vice President, Accounting and Financial Reporting and served as Vice President, Finance from May 2013 to April 2017. Prior to joining Regulus Therapeutics, Mr. Chevallard held various senior roles in corporate finance, accounting and financial reporting including Controller and Senior Director, Finance of Prometheus Laboratories Inc. (acquired by Nestlé Health Science in July 2011). Prior to joining Prometheus, Mr. Chevallard spent approximately five years in public accounting at Ernst & Young, LLP in their assurance services practice. He received his Bachelor of Accountancy from the University of San Diego and is a Certified Public Accountant in the state of California.

What is Daniel R. Chevallard's net worth?: The estimated net worth of Daniel R. Chevallard is at least $21,484.26 as of February 27th, 2024. Mr. Chevallard owns 102,306 shares of Viracta Therapeutics stock worth more than $21,484 as of December 21st. This net worth approximation does not reflect any other investments that Mr. Chevallard may own. Learn More about Daniel R. Chevallard's net worth.
How do I contact Daniel R. Chevallard?: The corporate mailing address for Mr. Chevallard and other Viracta Therapeutics executives is 2533 S. COAST HWY. 101 SUITE 210, CARDIFF CA, 92007. Viracta Therapeutics can also be reached via phone at (858) 400-8470 and via email at [email protected]. Learn More on Daniel R. Chevallard's contact information.
Has Daniel R. Chevallard been buying or selling shares of Viracta Therapeutics?: Daniel R. Chevallard has not been actively trading shares of Viracta Therapeutics over the course of the past ninety days. Most recently, Daniel R. Chevallard sold 3,405 shares of the business's stock in a transaction on Tuesday, February 27th. The shares were sold at an average price of $0.73, for a transaction totalling $2,485.65. Following the completion of the sale, the chief financial officer now directly owns 102,306 shares of the company's stock, valued at $74,683.38. Learn More on Daniel R. Chevallard's trading history.
Who are Viracta Therapeutics' active insiders?: Viracta Therapeutics' insider roster includes Daniel Chevallard (CFO), Lisa Rojkjaer (Insider), and Ivor Royston (CEO). Learn More on Viracta Therapeutics' active insiders.
Are insiders buying or selling shares of Viracta Therapeutics?: In the last year, insiders at the sold shares 1 times. They sold a total of 3,405 shares worth more than $2,485.65. The most recent insider tranaction occured on February, 27th when CFO Daniel R Chevallard sold 3,405 shares worth more than $2,485.65. Insiders at Viracta Therapeutics own 10.7% of the company. Learn More about insider trades at Viracta Therapeutics.
Information on this page was last updated on 2/27/2024.

Daniel R. Chevallard Insider Trading History at Viracta Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
2/27/2024	Sell	3,405	$0.73	$2,485.65	102,306
11/28/2023	Sell	3,720	$0.50	$1,860.00	98,822
8/28/2023	Sell	3,512	$1.45	$5,092.40	95,653
5/25/2023	Sell	3,635	$1.42	$5,161.70	92,277
2/27/2023	Sell	3,599	$1.68	$6,046.32	89,023
11/28/2022	Sell	3,532	$2.72	$9,607.04	85,733
8/26/2022	Sell	3,655	$4.02	$14,693.10	82,376
5/26/2022	Sell	3,596	$1.90	$6,832.40	79,142
2/28/2022	Sell	3,998	$2.78	$11,114.44
11/29/2021	Sell	4,325	$4.82	$20,846.50
11/26/2021	Sell	3,254	$4.80	$15,619.20

Daniel R. Chevallard Buying and Selling Activity at Viracta Therapeutics

Viracta Therapeutics Company Overview

Viracta Therapeutics, Inc., a clinical-stage precision oncology company, focuses on the treatment and prevention of virus-associated cancers that impact patients worldwide. Its lead product candidate is Nana-val, an all-oral combination therapy of its proprietary investigational drug, nanatinostat, and the antiviral agent valganciclovir. The company's Nana-val is in various ongoing clinical trials, including NAVAL-1, an open-label Phase 2 basket trial for the treatment of multiple subtypes of relapsed/refractory Epstein-Barr virus-positive (EBV+) lymphoma, as well as an open-label Phase 1b/2 trial for the treatment of EBV+ recurrent or metastatic nasopharyngeal carcinoma and other EBV+ solid tumors. Its product pipeline also includes vecabrutinib, a clinical-stage product candidate; and VRx-510, a preclinical product candidate. The company is headquartered in Cardiff, California.

Today's Range

Now: $0.21

$0.21

$0.26

50 Day Range

MA: $0.19

$0.14

$0.26

2 Week Range

Now: $0.21

$0.13

$1.31

Volume

1,701,261 shs

Average Volume

775,484 shs

Market Capitalization

$8.35 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.67